Antioxidant and Antiproliferative Activities of Hemp Seed Proteins ( L.), Protein Hydrolysate, and Its Fractions in Caco-2 and THP-1 Cells.
1/5 보강
This study evaluated the in vitro antioxidant and antiproliferative activity of hemp seed ( L.) protein isolate, protein hydrolysate, and its fractions.
APA
Juárez-Cruz MV, Jiménez-Martínez C, et al. (2025). Antioxidant and Antiproliferative Activities of Hemp Seed Proteins ( L.), Protein Hydrolysate, and Its Fractions in Caco-2 and THP-1 Cells.. International journal of molecular sciences, 26(23). https://doi.org/10.3390/ijms262311741
MLA
Juárez-Cruz MV, et al.. "Antioxidant and Antiproliferative Activities of Hemp Seed Proteins ( L.), Protein Hydrolysate, and Its Fractions in Caco-2 and THP-1 Cells.." International journal of molecular sciences, vol. 26, no. 23, 2025.
PMID
41373886 ↗
Abstract 한글 요약
This study evaluated the in vitro antioxidant and antiproliferative activity of hemp seed ( L.) protein isolate, protein hydrolysate, and its fractions. The protein hydrolysate was obtained through sequential enzymatic digestion using pepsin and pancreatin, achieving a degree of hydrolysis of 48.11%. The hydrolysate was then fractionated by ultrafiltration. Assays conducted on Caco-2 (colorectal cancer) and THP-1 (leukemia) cell lines revealed that the higher-molecular-weight fraction of (>10 kDa) exhibited the strongest, concentration-dependent antiproliferative effect, as determined by the neutral red uptake (NRU) assay for Caco-2 cells and the MTT assay for THP-1 cells. Furthermore, a significant intracellular antioxidant activity was observed, particularly in the whole hydrolysate and its low-molecular-weight fractions, as measured by the DCFH-DA assay in Caco-2 cells. The results suggest the potential application of hemp seed protein hydrolysate and its fractions as antioxidant and chemoprotective supplements in oncologic therapies.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Association of patient health education with the postoperative health related quality of life in low- intermediate recurrence risk differentiated thyroid cancer patients.
- Early local immune activation following intra-operative radiotherapy in human breast tissue.